Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy
Related Experiment Video
Updated: Sep 6, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Prashant Pandey1, Dilip Kumar Arya1, Mohan Kumar Ramar2
1Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow 226 025, India.
Abstract:
Breast cancer (BC) is the second most common cancer in women, with a high morbidity rate. The human epidermal growth factor receptor HER2 is a growth-promoting protein that is overexpressed in 15-20% of breast cancers (HER2+ BCs) and is often associated with clinically aggressive disease. Targeting this oncogene has resulted in significant improvements in survival outcomes for HER2+ BC patients. Several HER2-targeted therapies are currently available, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates. These therapeutics have improved clinical outcomes in HER2+ BC patients with metastatic disease, increasing the median overall survival (OS) rate. Despite these advancements, there are still many challenges to overcome. In recent times, there has been a significant increase in the use of engineered nanomaterials as efficient cancer therapeutics. In this review, we summarize the application of nanomaterials in HER2+ BC therapy using selected examples.
Insights
This review covers how nanomaterials can improve breast cancer treatment for HER2-positive patients. Nanomedicine offers new ways to target HER2+ breast cancer effectively.
Area of Science:
- Oncology
- Nanotechnology
- Biomedical Engineering
Background:
- Breast cancer (BC) is a leading cause of cancer death in women.
- HER2-positive (HER2+) BC, overexpressed in 15-20% of cases, is often aggressive.
- Current HER2-targeted therapies have improved survival but face challenges.
Purpose of the Study:
- To review the application of engineered nanomaterials in HER2+ BC therapy.
- To highlight selected examples of nanomaterial-based therapeutic strategies.
- To discuss the potential of nanomedicine in overcoming current treatment limitations.
Main Methods:
- Literature review of recent advancements in nanomaterial applications for HER2+ BC.
- Analysis of selected examples showcasing nanomaterial-based drug delivery and targeting.
- Synthesis of information on the efficacy and challenges of nanotherapeutics.
Main Results:
- Nanomaterials show promise as efficient carriers for HER2-targeted therapies.
- Engineered nanoparticles can enhance drug delivery and reduce side effects.
- Selected examples demonstrate improved therapeutic outcomes in preclinical or clinical settings.
Conclusions:
- Nanomaterials represent a significant advancement in the treatment of HER2+ breast cancer.
- Further research and development are needed to fully realize the potential of nanomedicine in clinical practice.
- Nanotechnology offers a promising avenue for developing next-generation HER2-targeted therapies.
